Breaking News

Galapagos Earns Janssen Milestone

January 16, 2013

Delivers second preclinical drug candidate

Galapagos NV has identified a second preclinical compound in its alliance with Janssen Pharmaceutica NV, triggering a $5.3 million milestone payment to Galapagos.
 
The two companies entered the alliance in 2007, under which Janssen has option rights to acquire worldwide, commercial licenses to certain Galapagos internal programs.  
 
"We are very pleased to announce the delivery of a second candidate drug in the alliance with Janssen," said Onno van de Stolpe, chief executive officer of Galapagos. "Galapagos is progressing multiple programs successfully across different alliances and delivering promising candidate drugs."

Related Contract Manufacturing:

blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent